ACA
DRNA

Avoro Capital Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Avoro Capital Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-46,082
Closed -$271K – 50
2016
Q3 		$271K Buy
+46,082
New +$162K 0.05% 44

Other funds holding DRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Avoro Capital Advisors's DRNA Position: Q4 2016 in Review

Avoro Capital Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2016, closing a stake of 46,082 shares — an estimated $271K sold.

Avoro Capital Advisors first reported a position in DRNA in Q3 2016 and held it in 1 quarter. The position peaked at $271K in Q3 2016. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2016.

  • Avoro Capital Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Avoro Capital Advisors sold 46,082 Dicerna Pharmaceuticals, Inc. shares in Q4 2016, an estimated $271K.
  • Avoro Capital Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Avoro Capital Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $271K in Q3 2016.
  • 50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2016.

Based on Avoro Capital Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.